NEURIM: A Study on Neurexan®
The NEURIM study shows that the Heel medicine Neurexan® reduces the stress response in stress-relevant brain areas.1 Results have now been published in a first article1 in the Nature Publishing Group journal “Scientific Reports”.
The NEURIM study has been conducted at the universities of Magdeburg and Tübingen. It was led by a psychiatrist and researcher in the field of biomedical image analysis, Prof. Dr. Martin Walter, who is now at the at the university of Jena. He was supported by a team of colleagues from the universities of Tübingen and Magdeburg.
The study showed that Neurexan® (Nx4) reduced the brain’s response in the amygdala and other stress-relevant brain areas to negative emotional stimuli. This clinical trial used state of the art technology and has now been published in Scientific Reports, a peer-reviewed journal from the Nature Publishing Group.
The NEURIM Study
39 mildly to moderately stressed healthy volunteers received Neurexan® in a randomized, placebo-controlled, double-blind, two-period crossover study. Afterwards, their brain responses were evaluated amongst others with fMRI (functional magnetic resonance imaging), a method to assess whether an area of the brain is active or not, while the participants were either at rest or under emotional stress.
The amygdala, an important part of the limbic system and often called the stress center in the brain, is activated by stress. In return vigilance and anxiety in the brain increase, leading to an increased stress response in the body. Neuroimaging this stress response in the amygdala via the fMRI technology is in the focus of this publication.
First results of the NEURIM study published
The first publication on the NEURIM study focuses on results showing that Neurexan® reduced the brain’s response in the amygdala to negative emotional stimuli. Participants also showed reduced activity in other stress relevant brain regions such as the para-hippocampal and temporal areas, supporting the multitarget effect of Neurexan®. Additionally, the onset of action was fast: After a single dose of Neurexan® the effects in the brain could be observed within 40−60 minutes.
Neurexan® is an effective, fast acting multi-component, multi-target natural medication that provides relief from restlessness and sleep disorders. Neurexan has a very good safety profile, is non-addictive, non-sedative, does not cause daytime drowsiness or concentration deficits and is very well tolerated.
1 Herrmann, L., Vicheva, P., Kasties, V. et al. fMRI Revealed Reduced Amygdala Activation after Nx4 in Mildly to Moderately Stressed Healthy Volunteers in a Randomized, Placebo-Controlled, Cross-Over Trial. Sci Rep 10, 3802 (2020). https://doi.org/10.1038/s41598-020-60392-w